Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Accumulated Expenses: 2015-2024

Historic Accumulated Expenses for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to $60.1 million.

  • Syndax Pharmaceuticals' Accumulated Expenses rose 60.23% to $77.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.1 million, marking a year-over-year increase of 60.23%. This contributed to the annual value of $60.1 million for FY2024, which is 50.78% up from last year.
  • As of FY2024, Syndax Pharmaceuticals' Accumulated Expenses stood at $60.1 million, which was up 50.78% from $39.9 million recorded in FY2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Accumulated Expenses peaked at $60.1 million during FY2024, and registered a low of $14.5 million during FY2021.
  • For the 3-year period, Syndax Pharmaceuticals' Accumulated Expenses averaged around $41.4 million, with its median value being $39.9 million (2023).
  • Per our database at Business Quant, Syndax Pharmaceuticals' Accumulated Expenses surged by 138.12% in 2020 and then tumbled by 40.41% in 2021.
  • Over the past 5 years, Syndax Pharmaceuticals' Accumulated Expenses (Yearly) stood at $24.3 million in 2020, then crashed by 40.41% to $14.5 million in 2021, then spiked by 67.83% to $24.3 million in 2022, then soared by 64.18% to $39.9 million in 2023, then spiked by 50.78% to $60.1 million in 2024.